Behçet’s disease

Yıl 2011, Cilt: 1 Sayı: 1, 65 - 73, 31.01.2014

Emre Aytuğar Filiz Namdar Pekiner

Öz

Behcet’s Disease (BD) is a chronic multisystem vascularinflammatory disorder, firstly described by the Turkish dermatologist Hulusi Behçet (1889-1948) in 1937. It is thought to be auto-immune and characterized by attacks of oral and genital ulcers, arthritis, cutaneous lesions, ocular lesions, involvement of the gastrointestinal tract and central nervous system. However the etiology of BD is still unknown, infectious, psychological, genetic and immunological factors can be counted as the possible etiologic factors. This review updates the BD in point of epidemiology, clinical symptoms, diagnosis, prognosis and etiopathology.

Key words: Behçet’s disease, epidemiology, etiopathology

Anahtar Kelimeler

-

Behçet hastalığı

Öz

Behçet Hastalığı (BH) ilk olarak 1937 yılında Türk Dermatolog Hulusi Behçet (1889-1948) tarafından tanımlanan kronik vasküler- enflamatuar multisistemik bir hastalıktır. Oto-immün olduğu düşünülen hastalık, ataklarla seyreden oral ve genital aftlar, artrit, kutanöz lezyonlar, göz lezyonları, gastrointestinal sistem ve merkezi sinir sistem tutulumuyla karakterizedir. BH’nin etyolojisi günümüzde hala bilinmemekle birlikte olası etyolojik faktörler arasında enfeksiyöz, psikolojik, genetik ve immünolojik faktörler sayılabilmektedir. Bu derleme BH’yi epidemiyolojik, klinik belirtiler, diagnoz, prognoz ve etyopatogenetik bakımdan güncellemektedir.

Anahtar Kelimeler: Behçet hastalığı, epidemiyoloji, etyopatogenez

Anahtar Kelimeler

Behçet hastalığı, epidemiyoloji, etyopatogenez

Kaynakça

• Scully C, Gorsky M, Lozada-Nur F: The Diagnosis and management of recurrent aphthous stomatitis: a consensus approach. J Am Dent Assoc. 2003; 134: 200-207.
• Evereklioglu C: Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005;50:297-350.
• Karlidag R, Unal S, Evereklioglu C, Sipahi B, Er H, Yologlu S. Stressful life events, anxiety, depression and coping mechanisms in patients with Behcet’s disease. J Eur Acad Dermatol Venereol 2003;17:670-675.
• Al-Otaibi LM, Porte SR, Poite TWJ: Behçet’s Disease: A Review. J Dent Res, 2005; 84: 209-222.
• Pamuk ÖN, Çakır N. Behçet hastalığı epidemiyolojisi. T Klin J Int Med Sci 2005;1:3-9.
• Rhee SH, Kim YB, Lee ES: Comparison of Behçet’s Disease and Recurrent Aphthous Ulcer According to Characteristics of Gastrointestinal Symptoms. J Korean Med Sci 2005; 20; 971-976.
• Davatchi F, Shahram F, Akbarian M, Gharibdoost F, Chams C, Chams H, Mansoori P, Nadji A: Classification tree for the diagnosis of Behcet’s disease. In: Wechsler B, Godeau P (eds): Behcet’s disease. Excerpta Medica. Amsterdam, 1993; 245-248.
• Cakir N, Dervis E, Benian O: Prevalence of Behcet’s disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 2004; 22: 53-5.
• Kotake S, Namba K, Higashi K: The change of clinical manifestations of patients with Behcet’s disease in Japan. Adv Exp Med Biol 2003; 528:83-84.
• Saylan T, Mat C, Fresko I, Melikoğlu M: Behçet’s disease in the Middle East. Clinics in Dermatology 1999; 17: 209-223.
• Al-Dalaan AN, al Balaa SR, el Ramahi K, al-Kawi Z, Bohlega S, Bahabri S, al Janadi MA. Behçet’s disease in Saudi Arabia. J Rheumatol. 1994;21:658-61.
• Al-Fahad SA, Al-Araji AH: Neuro-Behcet’s disease in Iraq: a study of 40 patients. Journal of the Neurological Sciences, 1999; 170: 105-111.
• Marshall SE: Behçet’s disease. Best Practice & Research Clinical Rheumatology 2004;18: 291-311.
• Demirhindi O, Yazıcı H, Binyıldız P, ve ark. Silivri fener köyü ve yöresinde Behçet hastalığı sıklığı ve bu hastalığın toplum içinde taranmasında kullanılabilecek bir yöntem. Cerrahp Tıp Fak Derg. 1981;12:509-514.
• Yurdakul S, Yazici H, Tuzun Y, ve ark. THA arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis 1983; 42: 505-515.
• Gul A, Inanc M, Ocal L: Familial aggregation of Behcet’s disease in Turkey. Ann Rheum Dis 2000; 59:622-625.
• Yazici H, Fresko I, Tunc R: Behcet’s syndrome: pathogenesis, clinical manifestations and treatment in Vasculitis by Gene V. Ball, S. Louis Bridges ed. Oxford University Press, USA; 2002;1:406-32.
• Tüzün Y, Yurdakul S, Mat C, Özyazgan Y, Hamuryudan V, Tüzün B, Yazıcı H: Epidemiology of Behçet’s Syndrome in Turkey. International Journal of Dermatology 1996; 35: 618-620.
• Gul A, Esin S, Dilsen N: Immunohistology of skin pathergy reaction in Behçet’s disease. British Journal of Dermatology 1995; 132: 901-907.
• Demirkesen C, Tuzuner N, Mat C: Clinicopathologic evaluation of nodular cutaneous lesions of Behcet syndrome. Am J Clin Pathol 2001; 116: 341-346.
• Saricaoglu H, Karadogan SK, Bayazit N, Yucel A, Dilek K, Tunali S. Clinical features of late onset Behcet’s disease: report of nine cases. Int J Dermatol 2006;45:1284-1287.
• Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM: Epidemiology and clinical characteristics of Behçet’s disease in the US: a population based study.Arthritis Rheum. 2009;61:600-604.
• Yaylalı GF: Denizli ve Çevresinde Ailesel Akdeniz Ateşi ve Behçet Hastalığı Prevalansı: “Sıfır Hasta” Modelinin uygulanması. Uzmanlık tezi. Denizli, 2003.
• Ando K, Fujino Y, Hijikata K: Epidemiological features and visual prognosis of Behçet’s disease. Jpn J Ophthalmol 1999;43: 312-317.
• Bayraktar Y, Balkanci F, Bayraktar M: Budd-Chiari syndrome: a common complication of Behcet’s disease. Am J Gastroenterol 1997; 92: 858-86.
• Benezra D, Cohen E: Treatment and visual prognosis in Behçet’s disease. Br J Ophthalmol 1986;70: 589-592.
• Sakamoto M, Akazawa K, Nishioka Y: Prognostic factors of vision in patients with Behcet disease. Ophthalmology 1995;102:317-21.
• Kural-Seyahi E, Fresko I, Seyahi N: The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003; 82:60-76.
• Karaca M :Ailevi Behçet Hastalığı Olgularında Hedef Organ İlişkilerinin Faktör Analizi İle İncelenmesi. Uzmanlık Tezi, İstanbul, 2008.
• Zouboulis C.C: Epidemiology of Adamantiades-Behcet’s disease. Ann Med Interne 1999; 150: 488-498.
• Gurler A, Boyvat A, Tursen U: Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J 1997; 38: 423-427.
• Yazici H, Fresko I: Behcet’s disease and other autoinflammatory conditions: what’s in a name? Clin Exp Rheumatol 2005; 23 : 1-2.
• Ilknur T, Pabuccuoglu U, Akin C, Lebe B, Gunes AT. Histopathologic and direct immunofluorescence findings of the papulopustular lesions in Behcet’s disease. Eur J Dermatol 2006;16:146-150.
• Chang HK, Kim JU, Cheon KS, Chung HR , Lee KW, Lee IH: HLA-B51 and its allelic types in association with Behçet’s disease and recurrent aphthous stomatitis in Korea. Clin Exp Rheumatol. 2001 ; 19: 31-35.
• Yıldırım M, Kılınç Y, Ceyhan MA. Behçet hastalığı patogenezindeki yenilikler S.D.Ü.Tıp Fak.Derg. 2009;16:29-34.
• Kılınç Y: Behçet Hastalarında Yaşam Kalitesi Anksiyete ve Depresyon, Uzmanlık Tezi, Isparta, 2007.
• Aslan SH, Soylu MB, Alparslan ZN, Ünal M: Behçet Hastalığında psikososyal etkenler ve ruhsal bulgular. Türk Psikiyatri Dergisi 1996;1:215-221.
• Yazici H, Chamberlain MA, Schreuder I: HLA antigens in Behcet’s disease: a reappraisal by a comparative study of Turkish and British patients. Ann Rheum Dis. 1980 ;39:344-348.
• Ohno S, Asanuma T, Sugiura S: HLA-Bw51 and Behcet’s disease. JAMA 1978; 240: 529.
• Celenk C, Aydin F, Unsal M: Pulmonary alterations in Behcet’s disease. Europan Journal of Radiology, 2009;70:317-319.
• Yazici H, Chamberlain MA, Schreuder GM: HLA B5 and Behcet’s disease. Ann Rheum Dis. 1983;42:602-603.
• Verity DH, Marr JE, Ohno S: Behcet’s disease, the Silk Road and HLA- B51: historical and geographical perspectives. Tissue Antigens. 1999; 54: 213-220.
• Gul A, Uyar FA, Inanc M: Lack of association of HLA-B*51 with a severe disease course in Behcet’s disease. Rheumatology 2001; 40: 668-672.
• Muftuoglu AU, Yazici H, Yurdakul S: Behcet’s disease: lack of correlation of clinical manifestations with HLA antigens. Tissue Antigens. 1981; 17: 226-230.
• Güner İ, Özmen D, Bayındır O: Sitokinler: Cytokines. T Klin J Med Sci, 1997;17:65-74.
• Houman H, Hamzaoui A, Ghorbal IB, Khanfir M, Feki M, Hamzaoui K: Abnormal expression of chemokine receptors in Behçet’s disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. Journal of Autoimmunity 2004;23: 267-273.
• Turan B, Gallati H, Erdi H, Gürler A, Michel BA, Villiger PM: Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet’s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997 ; 24 : 128-132.
• Akman-Demir G, Tüzün E, Içöz S, Yeşilot N, Yentür SP, Kürtüncü M, Mutlu M, Saruhan-Direskeneli G: Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine, 2008; 44: 373-376.
• Curnow SJ, Pryce K, Modi N, Knight B, Graham EM, Stewart JE, Fortune F, Stanford MR, Murray PI, Wallace GR: Serum cytokine profiles in Behçet’s disease: Is there a role for IL-15 in pathogenesis? Immunol Lett. 2008;121:7-12.
• Hamuryudan V, Yurdakul S, Serdaroglu S, Tuzun Y, Rosenkaimer F, Yazici H. Topical alpha interferon in the treatment of oral ulcers in Behcet’s syndrome: a preliminary report. Clin Exp Rheumatol 1990;8:51-54.
• Mochizuki M, Morita E, Yamamoto S, Yamana S: Characteristics of T cell lines established from skin lesions of Behcet’s disease. Journal of Dermatological Science 1997; 15: 9-13.
• Hatemi G, Bahar H, Uysal S: The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis 2004; 63: 1450-1452.
• Yazici H, Mat C, Deniz S: Sebum production is increased in Behcet’s syndrome and even more so in rheumatoid arthritis. Clin Exp Rheumatol 1987; 5: 371-374.
• Chun SI, Su WP, Lee S: Histopathologic study of cutaneous lesions in Behcet’s syndrome. J Dermatol. 1990;17:333-341.
• Soto-Rojas AE, Kraus A: The oral side of Sjögren Syndrome. Diagnosis and treatment. A review. Archives of Medical Research 2002;33: 95-106.
• Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T: Foxp3+CD25+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunological Reviews, 2006;212:8-27.
• Alpsoy E: Behçet hastalığında deri ve mukoza belirtilerinin tedavisi. Türkiye Klinikleri J Int Med Sci 2005;1:66-70.
• Demirel GY: Treg Hücreler ve Genomiks. Türkiye Klinikleri J Int Med Sci 2007;3:33-38.
• Ghate JV, Jorizzo JL: Behcet’s disease and complex aphthosis. J Am Acad Dermatol 1999;40:1-18.
• Hamzaoui K, Kamoun M, Houman H, Hentati F, Hazma MH, Ayed K, Hamzaoui A: Discrepancies of NKT cells expression in peripheral blood and in cerebrospinal fluid from Behçet’s disease. Journal of Neuroimmunology 2006; 175: 160-168.
• Hamzaoui K, Hamzaoui A, Houman H: CD4+CD25+ regulatory T cells in patients with Behçet’s disease. Clin Exp Rheumatol. 2006 ; 24 : 71-78.
• Criteria for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease. Lancet 1990; 335:1078-1080.
• Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 1990;332:281-285.
• Melikoglu M, Uysal S, Krueger JG: Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol 2006; 177: 6415-6421.
• Matsumoto T, Uekusa T, Fukuda Y: Vasculo-Behcet’s disease: a pathologic study of eight cases. Hum Pathol. 1991 ;22:45-51.
• Gul A, Ozbek U, Ozturk C, Inanc M, Konice M, Ozcelik T: Coagulation factor V gene mutation increases the risk of venous thrombosis in Behcet’s disease. Br J Rheumatol 1996 ; 35:1178-1180.
• Oh SH, Han EC, Lee JH, Bang D: Comparison of the clinical features of recurrent aphthous stomatitis and Behçet’s disease. Clinical and Experimental Dermatology 2009;34: 208-212
• Koç AF, Yerdelen D, Bozdemir H, Erken E: EEG Findings in Behçet’s Syndrome. J Neurol. Sci[Turk] 2005; 22:176-185.
• Fukuda Y, Watanabe I, Hayashi H: Pathological studies on Behcet’s disease. Ryumachi. 1980 ; 20:268-275.
• Bilgici B, Bedir A, Şentürk N, Alvur M, Aydin F, Turanli AY: Genotoxicity assessment using comet assay in Behcet’s disease patients. Mutation Research,2005; 578: 170-174.
• Kotter I, Zierhut M, Eckstein AK: Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87: 423-431.
• Akman-Demir G, Baykan-Kurt B, Serdaroglu P: Seven-year follow-up of neurologic involvement in Behcet syndrome. Arch Neurol, 1996; 53: 691
• Diri E, Mat C, Hamuryudan V: Papulopustular skin lesions are seen more frequently in patients with Behcet’s syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001; 60: 1074-1076.
• Jorizzo JL, Abernethy JL, White WL, Mangelsdorf HC, Zouboulis CC, Sarica R, Gaffney K, Mat C, Yazici H, al Ialaan A: Mucocutaneous criteria for the diagnosis of Behcet’s disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995;32:968-976.
• Mat C, Yazici H, al Ialaan A: Mucocutaneous criteria for the diagnosis of Behcet’s disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995;32:968-976.
• Alpsoy E, Durusoy C, Yilmaz E: Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002 ;138:467-471.
• Hamuryudan V, Er T, Seyahi E, Akman C, Tuzun H, Fresko I, Yurdakul S, Numan F, Yazici H: Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004;117:867-870.
• Tunc R, Saip S, Siva A: Cerebral venous thrombosis is associated with major vessel disease in Behcet’s syndrome. Ann Rheum Dis 2004; 63: 1693-1694.
• Azizlerli G, Ozarmagan G, Ovul C, ve ark. A new kind of skin lesion in Behcet’s disease: extragenital ulcerations. Acta Derm Venereol 1992; 72: 286.
• A.l-Aboosi MM, al Salem M, Saadeh A, al-Jamal M, Hijawi M, Khammash M, Sharma RV. Behçet’s disease: clinical study of Jordanian patients. Int J Dermatol. 1996 ;35:623-625.
• Baixauli A, Calvo J, Tamarit JJ, Campos C, García S, Herrera A. Behcet’s disease: retrospective study An Med Interna. 2001;18: 405-410.
• Karaca S, Seyhan M, Senol M, Harputluoglu MM, Ozcan A: The effect of gastric Helicobacter pylori eradication on recurrent aphthous stomatitis. International Journal of Dermatology 2008;47:615-617.